| (c) | Explain: | | | AP-481 |
|-----|--|----------------|----------------------------|---------------------------------------|
| | (i) Antibiotics | | · · | ester-IV Examination |
| | (ii) MIC. | 4. | | OBIOLOGY (icrobiology) |
| | OR | | | |
| (d) | Enlist major antimicrobial agents against | bacteria | Time: Three Hours] | [Maximum Marks: 80 |
| | and fungi. Explain any one in detail. | 4 | Note:—(1) All questi | ons are compulsory. |
| (e) | Discuss agar dilution method of antim | icrobial | (2) Draw we | ll labelled diagrams, wherever |
| | susceptibility testing. | : 4 | necessary | • |
| (f) | Give characteristics of ideal chemotherapeut | ic agent. 4 | 1. (A) Fill in the blanks: | 2 |
| | | | (i) Infection which | h is initiated by physician is called |
| | | | as | |
| | | | (ii) The causative | agent of Typhus fever is |
| | | | (iii) The long form | of ELISA is |
| | | | (iv) test | is performed for serrological |
| | | | diagnosis of ty | |
| UWO | 12429 6 | 625 | UWO42429 | 1 (Contd.) |

| (B) | Cho | Streptolysin O is a oxygen haemolysin. | | 2 | | (e) | Explain in brief IgA. | . 4 | |
|----------|------|--|------------------|------------------|--|--|---|---------------|--|
| | (i) | | | haemolysin. | | (f) | Explain monoclonal antibodies in brief. | 4 | |
| | | (a) (b) | Stable Labile | | 5. | | cribe morphology, pathogenicity, lab-diagno | sis an | |
| | | (c) | Mobile | | | prop | ohylaxis of Mycobacterium Tuberculosis. OR | 12 | |
| | (6 | (d) | Stagnant | | | | OK | | |
| | (ii) | Germ tube is produced in | | . | Describe morphology, pathogenicity, lab-c | | | liagnosis and | |
| | | (a) Rickettsia | | prop | hylaxis of Vibrio Cholerae. | 12 | | | |
| | | (b) | Candida albicans | ans | 6. | Des | cribe in detail Polio Virus. | 12 | |
| | | (c) |) Staphylococcus | | | | OR | | |
| | | (d) | Vibrio cholerae. | | | Wha | What is AIDS? Describe in detail pathogenicity, l | | |
| Ŷ, | | Immunity acquired by foetus from mother is called as | | s from mother is | diagnosis and prophylaxis of its causative | | | 12 | |
| | j | (a) Herd Immunity | | 7. | (a) | Discuss broth dilution method of antimic susceptibility testing. | | | |
| | | (b) | | | | | | 4 | |
| | | (c) | | P | | (b) | Explain mechanism of action of Rifampicin v | with its | |
| | | (d) | Racial Immunity | | | | clinical use. | 4 | |
| UWO-4242 | 9 | | 2 | (Contd.) | UWO | -424 | 29 .5 (0 | Contd.) | |

| * | | (iv) | Alle | ergic reactions are caused by | * | | |
|------|-----|--|-------|-------------------------------------|------|------|--|
| | | | (a) | Ig G antibodies | | | |
| | | | (b) | Ig M antibodies | | | |
| | | | (c) | Ig A antibodies | | | |
| | | | (d) | Ig E antibodies | | | |
| • | (C) | Ans | wer | in one sentence : | | 4 | |
| | | (1) | Wh | at is attenuation? | | | |
| | | (2) | Def | fine pathogenicity and virulence. | | | |
| | | (3) | Def | fine nosocomial infection. | | | |
| | | (4) | Wi | nat is carrier? | | | |
| 2. | (a) | Dif | feren | tiate between Exotoxin and Endotor | cin. | 4 | |
| | (b) | Discuss normal flora of respiratory tract. | | | | | |
| | (c) | W | at is | Epidemiology? Give its classificati | on. | 4 | |
| | | * | | OR | | | |
| | (d) | Ex | plain | air-borne transmission of diseases. | | 4 | |
| i ro | /Ω4 | 2429 | | 3 | (Con | td.) | |

www.sgbauonline.com

| | (e) | Explain microbial enzymes as virulence fa | actor. 4 | | | |
|-----|------------|--|-------------|---|--|--|
| | (f) | How diseases can be controlled by blocking the | | | | |
| | | channels of airborne transmission? | 4 | | | |
| 3. | (a) | Explain in brief Spleen. | 4, | | | |
| | (b) | Explain Active Immunity. | 4 | | | |
| | (c) | Explain Type-II Hypersensitivity. | 4 | ı | | |
| | | OR | | | | |
| | (d) | Differentiate between Active and Passive I | mmunity. | | | |
| | | | 4 | | | |
| - | (e) | Explain Delayed type of Hypersensitivity | . 4 | | | |
| | (f) | Explain T-Cell in brief. | . 4 | | | |
| 4. | (a) | Explain in brief ELISA. | 4 | | | |
| | (b) | Explain the structure of IgG. | 4 | | | |
| | (c) | Define antigen. Explain factors determining an | tigenicity. | | | |
| | | | 4 | | | |
| | | OR | | | | |
| | (d) | Explain in brief agglutination reaction. | . 4 | | | |
| UWO | O 424 | 129 4 | (Contd.) | | | |